Key facts
- Inside Therapeutics’s last known valuation is $10.3M (Jun 2025).
- It has raised $2.5M; the latest was Early Stage VC ($1.1M) in Jun 2025.
- Notable investors include Newfund Management, SkalePark, AQUITI Gestion, Iventure (Grenoble), Microfluidics Innovation Center.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Inside Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Inside Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inside Therapeutics
Operator of a deep tech company intended to provide scientists with the right tools to help them test and scale up their production of liposomes, lipid nanoparticles, and polymer nano-drugs. The company specializes in lipid nanoparticle synthesis with microfluidics and is developing a microfluidic-based nanoparticle synthesis platform, enabling the healthcare industry to ensure seamless scalability all along the nanoparticle-based drug development process.
- Sector
- Business Products and Services (B2B)
- HQ
- Angoulême, France
- Founded
- 2022
- Employees
- 18
- Website
- insidetx.com/
- Ownership
- Privately Held (backing)
Inside Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inside Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inside Therapeutics in its N-PORT filings yet. We sweep new filings monthly.